SCHEMBL4849205

SCHEMBL4849205

CC1(C)CC(C)(C)c2cc(C#C[Si](C)(C)C)ccc2O1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.33
BACE1 P56817 9/20 0.33
CTSD P07339 8/20 0.33
RARB P10826 2/20 0.31
RARG P13631 2/20 0.31
SSTR5 P35346 1/20 0.31
CYP26A1 O43174 1/20 0.31
CYP3A4 P08684 1/20 0.31
RARA P10276 1/20 0.31
CRABP2 P29373 1/20 0.31
FTO Q9C0B1 1/20 0.31
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30
GABRA3 P34903 1/20 0.30
GABRA2 P47869 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9006905 0.88 AKR1B1 (0.32) AKR1B1RARBRARGCYP26A1CYP3A4
SCHEMBL5736955 0.86 RARB (0.33) BACE1RARBRARGCYP26A1CYP3A4
SCHEMBL5736909 0.80 AKR1B1 (0.35) AKR1B1BACE1CTSDSSTR5CYP26A1
SCHEMBL9180357 0.77 RARB (0.60) RARBRARGSSTR5CYP26A1CYP3A4
SCHEMBL5737195 0.77 CYP26A1 (0.47) AKR1B1RARBRARGSSTR5CYP26A1
SCHEMBL9175999 0.76 AKR1B1 (0.32) AKR1B1BACE1CTSDSSTR5
SCHEMBL5738447 0.75 RARB (0.42) AKR1B1RARBRARGSSTR5CYP26A1
SCHEMBL9024103 0.74 KDM4E (0.38) RARBRARGCYP26A1CYP3A4RARA
SCHEMBL8875331 0.73 AKR1B1 (0.40) AKR1B1RARBRARGSSTR5CYP26A1
SCHEMBL8865723 0.73 CYP3A4 (0.42) AKR1B1BACE1CTSDRARBRARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351737-B2 4-[(8-substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-YL-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity ALLERGAN, INC. (US) 2008-04-01 US disclosed
EP-1485368-A1 SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY Allergan, Inc. (US) 2004-12-15 EP disclosed
US-20040077721-A1 Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A ALLERGAN, INC. 2004-04-22 US disclosed
US-20030207937-A1 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity ALLERGAN, INC. 2003-11-06 US disclosed
WO-2003080594-A1 SUBSTITUTED CHROMAN DERIVATIVES HAVING CYTOCHROME P450RAI INHIBITORY ACTIVITY ALLERGAN, INC. (US) 2003-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077721-A1 Compositions and methods using compounds having cytochrome P450RAI inhibitory activity co-administered with vitamin A RARA, CYP2R1, RXRA AKR1B1 109/4885BACE1 2572/4885CTSD 1300/4885
US-20030207937-A1 4-[(8-Substituted)-6-chromanoyl]-and 4-[8-substituted)-chroman-6-yl-ethynyl]-benzoic and phenylacetic acids, their esters and salts having cytochrome P450RAI inhibitory activity RXRA, RARA, CYP26A1 AKR1B1 108/4885BACE1 3711/4885CTSD 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.